Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

• Published in: Journal of clinical oncology Vol. 26; no. 21; pp. 3496 - 3502
• Main Authors: EVANS, Douglas B, VARADHACHARY, Gauri R, CHARNSANGAVEJ, Chusilp, LANO, Elizabeth A, HO, Linus, LENZI, Renato, ABBRUZZESE, James L, WOLFF, Robert A, CRANE, Christopher H, SUN, Charlotte C, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, HUAMIN WANG, CLEARY, Karen R, STAERKEL, Gregg A
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 20.07.2008; Lippincott Williams & Wilkins
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Chemotherapy, Adjuvant - adverse effects; Chemotherapy, Adjuvant - methods; Combined Modality Therapy; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Neoadjuvant Therapy - methods; Neoplasm Staging; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Pancreaticoduodenectomy; Preoperative Care - methods; Radiotherapy, Adjuvant - adverse effects; Radiotherapy, Adjuvant - methods; Tumors; Antineoplastic agent; Human; Gemcitabine; Malignant tumor; Radiotherapy; Chemotherapy; Treatment; Cancerology; Antimetabolic; Pancreas cancer; Pyrimidine derivatives; Digestive diseases; Combined treatment; Fluorine Organic compounds; Preoperative; Pyrimidine nucleoside; Pancreas adenocarcinoma; Cancer; Pancreatic disease
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2007.15.8634

We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. Eligible patients with pancreatic head/uncinate process adenocarcinoma and radiographically defined potentially resectable disease received chemoradiation with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m(2) IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. The study enrolled 86 patients. At the time of restaging, disease progression or a decline in performance status precluded 13 patients from surgery. Seventy-three (85%) of 86 patients were taken to surgery, extrapancreatic disease was found in nine, and 64 (74%) of 86 underwent a successful PD. Median overall survival (86 patients) was 22.7 months with a 27% 5-year survival. Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 unresected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively. Preoperative gemcitabine-based chemoradiation followed by restaging and evaluation for surgery separated the study population into two different subsets: patients likely to benefit from PD (n = 64) and those in whom surgery would be unlikely to provide clinical benefit (n = 22). Furthermore, the encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.